These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 1003516)

  • 1. Role of donor immunocompetent cells in allograft rejection.
    Jacobs BB; Leonard L; Parks RC
    J Natl Cancer Inst; 1976 Aug; 57(2):345-8. PubMed ID: 1003516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered allotransplantability of BALB/c Leydig cell tumor after organ culture or cell suspension.
    Ninnemann JL; Good RA
    Transplantation; 1975 Jan; 19(1):42-7. PubMed ID: 804191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transplantation behavior of allotransplantable tumor lines derived from immunologically modified hosts.
    Parks RC; Jacobs BB
    J Natl Cancer Inst; 1975 May; 54(5):1079-83. PubMed ID: 236395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor acceptance modified by passage in hybrids with graft-versus-host reaction.
    Jacobs BB; Parks RC
    Exp Hematol; 1978 Nov; 6(10):785-90. PubMed ID: 33818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antigenic changes of DBA/2J mastocytoma cells when grown in the BALB/c mouse.
    Wolf JE; Faanes RB; Choi YS
    J Natl Cancer Inst; 1977 May; 58(5):1407-12. PubMed ID: 67213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alloreactivity and tumor antigens: generation of syngeneic antilymphoma killer lymphocytes by alloimmunization of mice with normal cells.
    Sensi ML; Parenza M; Parmiani G
    J Natl Cancer Inst; 1983 Feb; 70(2):291-7. PubMed ID: 6571938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are dead cells responsible for allogeneic growth of organ cultures and cell suspensions of BALB/c Leydig cell tumors?
    Jacobs BB
    Transplantation; 1976 May; 21(5):433-6. PubMed ID: 1273915
    [No Abstract]   [Full Text] [Related]  

  • 8. Altered host-allograft relationships for mouse tumors modified by prior passage in vitro and in vivo. II. Reactivity of lymphoid cells.
    Jacobs BB
    J Natl Cancer Inst; 1972 Oct; 49(4):1085-91. PubMed ID: 4404346
    [No Abstract]   [Full Text] [Related]  

  • 9. Immune inhibition of allogeneic lymphoma cells in the peritoneal cavity of mice.
    Fioretti MC; Libarati M; Bonmassar E; Cudkowicz G
    Cancer Res; 1975 Jan; 35(1):30-6. PubMed ID: 1089042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effector cell stimulation-inhibition of in vitro lymphoma cell DNA synthesis and correlation with in vivo antitumor response.
    Gordon WC; Prager MD
    Cancer Res; 1977 Feb; 37(2):507-13. PubMed ID: 832275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of a tumor allograft in BALB/c x DBA/2 F1 mice by pyran copolymer.
    Mohr SJ; Chirigos MA; Fuhrman F; Smith G
    Cancer Res; 1976 Apr; 36(4):1315-9. PubMed ID: 1260757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth of tumors in allogeneic hosts after organ culture explantation. II. Tumor-host interactions.
    Jacobs BB
    J Natl Cancer Inst; 1969 Apr; 42(4):537-43. PubMed ID: 4887236
    [No Abstract]   [Full Text] [Related]  

  • 13. Immune response of BALB/c X DBA/2F1 mice to a tumor allograft during pyran copolymer-induced tumor enhancement.
    Schultz RM; Woods WA; Mohr SJ; Chirigos MA
    Cancer Res; 1976 May; 36(5):1641-6. PubMed ID: 1268825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of marrow allograft resistance in mice with transplanted methylcholanthrene-induced sarcomas.
    Kumar V; Bennett M
    J Natl Cancer Inst; 1975 Aug; 55(2):489-92. PubMed ID: 240033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of transplant immunity: effect of donor leukocytes on thyroid allograft rejection.
    Talmage DW; Dart G; Radovich J; Lafferty KJ
    Science; 1976 Jan; 191(4225):385-8. PubMed ID: 1082167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Abeta(b-/-), H2-DM(-), and CIITA(-/-) in second-set skin allograft rejection.
    Felix NJ; de Serres S; Meyer AA; Ting JP
    J Surg Res; 2002 Feb; 102(2):185-92. PubMed ID: 11796017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell therapy with preimmunized effector cells mismatched for minor histocompatible antigens in the treatment of a murine mammary carcinoma.
    Morecki S; Yacovlev E; Gelfand Y; Uzi I; Slavin S
    J Immunother; 2001; 24(2):114-21. PubMed ID: 11265768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The allogeneic effect on tumor growth. II. Suppression of both ascitic and solid MOPC 315 plasmacytoma by the graft-vs-host reaction, with pathologic correlation.
    Osborne DP; Katz DH
    J Immunol; 1977 Apr; 118(4):1449-55. PubMed ID: 15035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-reactivity of incompatible lymphoid cells from f1 modified radiation chimeras to host tumour cells in vitro.
    Grant CK; Ilbery PL
    Biomedicine; 1973 Feb; 19(2):56-60. PubMed ID: 4581503
    [No Abstract]   [Full Text] [Related]  

  • 20. Quantitative studies of the growth and rejection of allogeneic tumour cells in mouse cerebrospinal fluid. Elimination in the absence of H-2 differences.
    Doherty PC; Zinkernagel RM
    Clin Exp Immunol; 1975 Feb; 19(2):355-66. PubMed ID: 813923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.